Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Expected Market Growth Rate for the Psoriasis Biosimilars Market?
The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $7.32 billion in 2024 to $8.16 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to the rising cost burden of original biologics, the clinical success and safety data of early entrants, the expansion of indications beyond psoriasis, the growth in chronic disease prevalence, and hospital procurement policy reforms.
The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $12.43 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing psoriasis incidence worldwide, switching policies and interchangeability laws, growth of biosimilar manufacturing, improved patient and physician education, and bundled pricing and value-based contracts. Major trends in the forecast period include innovative biosimilar manufacturing platforms, AI-driven patient stratification, the introduction of advanced drug delivery devices, the development of next-generation formulations, and strategic industry partnerships.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Psoriasis Biosimilars Market?
The rising psoriatic arthritis diagnosis rates are expected to propel the growth of the psoriasis biosimilars market going forward. Psoriatic arthritis refers to a chronic autoimmune condition that causes inflammation in the joints and skin, often affecting individuals with a history of psoriasis. The psoriatic arthritis diagnosis rates are increasing, particularly due to improved screening protocols among individuals with psoriasis, which enable earlier detection and more accurate diagnosis by identifying subtle joint symptoms that might have previously gone unnoticed. Psoriasis biosimilars help manage psoriatic arthritis by providing affordable alternatives to biologic therapies, effectively reducing joint inflammation and skin symptoms. For instance, in May 2024, according to the National Institutes of Health (NIH), a US-based government agency, in 2022, psoriatic arthritis (PsA) had a prevalence of 0.221% and an incidence rate of 13.54 per 100,000 people. Therefore, the rising psoriatic arthritis diagnosis rates are driving the growth of the psoriasis biosimilars market.
What Are the Emerging Segments in the Psoriasis Biosimilars Market?
The psoriasis biosimilars market covered in this report is segmented
1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars
What Are the Future Trends Forecasted for the Psoriasis Biosimilars Market?
Major companies operating in the psoriasis biosimilars market are focusing on introducing innovative solutions, such as biosimilars for plaque psoriasis, to enhance treatment accessibility, reduce healthcare costs, and improve patient outcomes. Biosimilars for plaque psoriasis are lower-cost, highly similar alternatives to approved biologic drugs used to treat the chronic autoimmune skin condition characterized by red, scaly patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based company that focuses on generic pharmaceuticals and biosimilars, launched the Pyzchiva autoinjector, the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. Designed to enhance patient adherence and quality of life, the autoinjector features accurate automatic dosing, reduced injection pain, a compact design, and flexible storage options for more comfortable self-administration.
Which Companies Hold the Largest Share in the Psoriasis Biosimilars Market?
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.
Get the full psoriasis biosimilars market report here:
Which Regions Are Driving the Most Demand in the Psoriasis Biosimilars Market?
North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment